CA Patent

CA3194494A1 — Orodispersible formulations

Assigned to Millicent Pharma Ltd · Expires 2022-04-07 · 4y expired

What this patent protects

An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.

USPTO Abstract

An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.

Drugs covered by this patent

Patent Metadata

Patent number: CA3194494A1
Jurisdiction: CA
Classification: —
Expires: 2022-04-07
Drug substance claim: No
Drug product claim: No
Assignee: Millicent Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.